

AMENDMENTS TO THE CLAIMS:

1-22. (canceled)

23. (previously presented) An antibody-producing cell line that produces a monoclonal antibody that binds specifically to a purified oligopeptide having the amino acid sequence LQLQPFQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO:12).

24. (original) An antibody produced from the cell line of claim 23.

25-28. (canceled)

29. (previously presented) The antibody of Claim 24, wherein the antibody is generated against (SEQ ID NO:12) LQLQPFQPQLPYPQPQLPYPQPQLPYPQPQPF.

30 (currently amended) An A method of generating an antibody-producing cell line; the method comprising:

immunizing an animal with ~~that that was generated by a response to~~ a purified oligopeptide having the amino acid sequence LQLQPFQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO:12) to generate a cell line producing an antibody, ~~and which produces a monoclonal antibody that binds specifically to a~~ said purified oligopeptide having the amino acid sequence LQLQPFQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO:12).

31. (previously presented) An antibody produced by the cell line of Claim 30.

32. (currently amended) An antibody that binds specifically to an antigen selected from a purified oligopeptide having the amino acid sequence (SEQ ID NO:12) LQLQPFQPQLPYPQPQLPYPQPQLPYPQPQPF; ~~or a tissue transglutaminase linked to SEQ ID NO:12.~~

33. (previously presented) The antibody of Claim 32, wherein the antibody is a polyclonal antibody.

34. (previously presented) The antibody of Claim 32, wherein the antibody is a monoclonal antibody.

35. (canceled)

36. (currently amended) ~~The antibody of Claim 32, wherein the~~ An antibody is produced by a cell line generated by a response to a tissue transglutaminase linked to SEQ ID NO:12 that binds specifically to said tissue transglutaminase linked to SEQ ID NO:12.

37. (canceled)

38. (previously presented) An antibody producing cell line that that was generated by an immune response to a tissue transglutaminase linked to SEQ ID NO:12.